共 159 条
[4]
Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores.[J].Bianco Cristiana;Jamialahmadi Oveis;Pelusi Serena;Baselli Guido;Dongiovanni Paola;Zanoni Irene;Santoro Luigi;Maier Silvia;Liguori Antonio;Meroni Marica;Borroni Vittorio;D’Ambrosio Roberta;Spagnuolo Rocco;Alisi Anna;Federico Alessandro;Bugianesi Elisabetta;Petta Salvatore;Miele Luca;Valenti Luca.Journal of Hepatology.2020, 4
[5]
FDA Approval Summary: Atezolizumab plus bevacizumab for the treatment of patients with advanced unresectable or metastatic hepatocellular carcinoma..[J].Casak Sandra J;Donoghue Martha;FashoyinAje Lola;Jiang Xiaoping;Rodriguez Lisa;Shen Yuan Li;Xu Yuan;Jiang Xiling;Liu Jiang;Zhao Hong;Pierce William F;Mehta Shubhangi;Goldberg Kirsten B;Theoret Marc R;Kluetz Paul G;Pazdur Richard;Lemery Steven J.Clinical cancer research : an official journal of the American Association for Cancer Research.2020, 7
[6]
TERT Promoter Mutation in Serum Cell-Free DNA Is a Diagnostic Marker of Primary Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease..[J]..Oncology.2020, 2
[10]
Update on NAFLD genetics: From new variants to the clinic
[J].
JOURNAL OF HEPATOLOGY,
2020, 72 (06)
:1210-1211